Results of a Phase II Study of Cladribine, Low Dose Cytarabine and Venetoclax, Alternating with Azacitidine and Venetoclax in Patients with Higher Risk Chronic Myelomonocytic Leukemia or Myelodysplastic Syndromes

被引：0

作者：

Montalban-Bravo, Guillermo ^{[1
]}

Short, Nicholas J. ^{[1
]}

Chien, Kelly S. ^{[1
]}

Valero, Yesid Alvarado ^{[1
]}

Daver, Naval ^{[1
]}

Borthakur, Gautam ^{[1
]}

Swaminathan, Mahesh ^{[1
]}

Maiti, Abhishek ^{[2
]}

Hammond, Danielle E. ^{[1
]}

Nogueras-Gonzalez, Graciela ^{[3
]}

Huang, Xuelin ^{[3
]}

Schneider, Heather ^{[4
]}

Shelly, Kristen ^{[4
]}

Kadia, Tapan M. ^{[1
]}

Kantarjian, Hagop M. ^{[4
]}

Garcia-Manero, Guillermo ^{[5
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX USA

[2] MD Anderson Canc Ctr, Dept Leukemia, Houston, TX USA

[3] Univ Texas MD Anderson Canc Ctr, Biostat, Houston, TX USA

[4] Univ Texas MD Anderson Canc Ctr, Leukemia, Houston, TX USA

[5] Univ Texas MD Anderson Canc Ctr, Houston, TX USA

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-178035

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：4

共 50 条

[31] Azacitidine Low-Dose Schedule In Low-Risk Myelodysplastic Syndromes. Preliminary Results of a Multicenter Phase II Study
Fili, Carla
Finelli, Carlo
Gobbi, Marco
Martinelli, Giovanni
Iacobucci, Ilaria
Ottaviani, Emanuela
Cocco, Lucio
Follo, Matilde
Candoni, Anna
Simeone, Erika
Miglino, Maurizio
Lauria, Francesco
Bocchia, Monica
Defina, Marzia
Clissa, Cristina
Lanza, Francesco
Curti, Antonio
Paolini, Stefania
Spedini, PierAngelo
Skert, Cristina
Bergonzi, Cesare
Malagola, Michele
Peli, Annalisa
Turra, Alessandro
Cattina, Federica
Colombi, Chiara
Russo, Domenico
BLOOD, 2010, 116 (21) : 1642 - 1642
[32] Phase II Study of Cladribine and Low-Dose Cytarabine (AraC) Alternating with Decitabine in Older Patients with Acute Myeloid Leukemia (AML)
Kadia, Tapan
Borthakur, Gautam
Ferrajoli, Alessandra
Daver, Naval
Jabbour, Elias
Pemmaraju, Naveen
Verstovsek, Srdan
Burger, Jan A.
Wierda, William G.
Konopleva, Marina
DiNardo, Courtney D.
Jain, Nitin
Brandt, Mark
Tuttle, Carla
Wang, Xuemei
Ravandi, Farhad
Garcia-Manero, Guillermo
Cortes, Jorge E.
Kantarjian, Hagop M.
BLOOD, 2014, 124 (21)
[33] Efficacy and safety of cladribine, low-dose cytarabine and venetoclax in newly diagnosed and relapsed/refractory acute myeloid leukemia: results of a single center study
Ting Zhu
Li Wang
Hui Jiang
Shujuan Huang
Haitao Xu
Anyou Wang
Xin Liu
Annals of Hematology, 2025, 104 (5) : 2745 - 2753
[34] A Phase II Study Of The Combination Of Azacitidine and Lenalidomide In Patients (pts) With Higher Risk Myelodysplastic Syndromes (MDS)
Garcia-Manero, Guillermo
Kadia, Tapan M.
Daver, Naval
Jabbour, Elias
Jain, Nitin
Cortes, Jorge E.
Estrov, Zeev
Borthakur, Gautam
Dong, Xiao Q.
Kumar, Veeral J.
Kantarjian, Hagop M.
BLOOD, 2013, 122 (21)
[35] A Phase 2 Study of Canakinumab in Patients with Lower-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia
Sevilla, Juan Jose Rodriguez
Adema, Vera
Chien, Kelly S.
Ganan-Gomez, Irene
Montalban-Bravo, Guillermo
Urrutia, Samuel
Joseph, Joby
Yang, Hui
Borthakur, Gautam
Short, Nicholas J.
Issa, Ghayas C.
Kadia, Tapan M.
Takahashi, Koichi
Hammond, Danielle E.
Garcia-Manero, Guillermo
BLOOD, 2023, 142
[36] Phase I/II clinical study of topotecan and cytarabine in patients with myelodysplastic syndrome, chronic myelomonocytic leukemia and acute myeloid leukemia
Weihrauch, MR
Staib, P
Seiberlich, B
Hoffmann, M
Diehl, V
Tesch, H
LEUKEMIA & LYMPHOMA, 2004, 45 (04) : 699 - 704
[37] Venetoclax Added to Cladribine (CLAD) plus Low Dose AraC (LDAC) Alternating with Azacitidine (AZA) Is Highly Active As Frontline Therapy in Older Patients with Newly Diagnosed Acute Myeloid Leukemia in a Phase 2 Study
Reville, Patrick K.
Kantarjian, Hagop
Borthakur, Gautam
Pemmaraju, Naveen
Daver, Naval
DiNardo, Courtney D.
Sasaki, Koji
Short, Nicholas
Issa, Ghayas C.
Ohanian, Maro
Jabbour, Elias
Montalban-Bravo, Guillermo
Maiti, Abhishek
Jain, Nitin
Ferrajoli, Alessandra
Bhalla, Kapil N.
Takahashi, Koichi
Rausch, Caitlin R.
Hammond, Danielle
Malla, Rashmi
Quagliato, Kelly
Brandt, Mark
Popat, Uday R.
Konopleva, Marina
Garcia-Manero, Guillermo
Ravandi, Farhad
Kadia, Tapan M.
BLOOD, 2022, 140 : 9041 - 9043
[38] Combination of vorinostat and low dose cytarabine for patients with azacitidine-refractory/relapsed high risk myelodysplastic syndromes
Prebet, Thomas
Braun, Thorsten
Beyne-Rauzy, Odile
Dreyfus, Francois
Stammatoullas, Aspasia
Wattel, Eric
Ame, Shanti
Raffoux, Emmanuel
Delaunay, Jacques
Charbonnier, Aude
Ades, Lionel
Fenaux, Pierre
Vey, Norbert
LEUKEMIA RESEARCH, 2014, 38 (01) : 29 - 33
[39] Rapid loss of response after withdrawal of treatment with azacitidine: a case series in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia
Voso, Maria Teresa
Breccia, Massimo
Lunghi, Monia
Poloni, Antonella
Niscola, Pasquale
Finelli, Carlo
Bari, Alessia
Musto, Pellegrino
Zambello, Renato
Fianchi, Luana
Alimena, Giuliana
Leone, Giuseppe
EUROPEAN JOURNAL OF HAEMATOLOGY, 2013, 90 (04) : 345 - 348
[40] A phase I/II study of the combination of quizartinib with azacitidine or low-dose cytarabine for the treatment of patients with acute myeloid leukemia or myelodysplastic syndrome
Swaminathan, Mahesh
Kantarjian, Hagop M.
Levis, Mark
Guerra, Veronica
Borthakur, Gautam
Alvarado, Yesid
DiNardo, Courtney D.
Kadia, Tapan
Garcia-Manero, Guillermo
Ohanian, Maro
Daver, Naval
Konopleva, Marina
Pemmaraju, Naveen
Ferrajol, Alessandra
Andreeff, Michael
Jain, Nitin
Estrov, Zeev
Jabbour, Elias J.
Wierda, William G.
Pierce, Sherry
Pinsoy, Maria Rhona
Xiao, Lianchun
Ravandi, Farhad
Cortes, Jorge E.
HAEMATOLOGICA, 2021, 106 (08) : 2121 - 2130

← 1 2 3 4 5 →